2025 H1 -tulosraportti
Vain PDF
186 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 000 | - | - | ||
| 25 455 | - | - | ||
| 500 | - | - | ||
| 500 | - | - | ||
| 15 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 H2 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 25.9.2025 | ||
2024 H2 -tulosraportti 9.4.2025 | ||
2024 Q2 -tulosraportti 30.9.2024 | ||
2024 H1 -tulosraportti 30.9.2024 | ||
2023 Q4 -tulosraportti 18.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11.3.Available on Spotify
·16.3.Gemini seems to have taken a page from Spotify's book: EXACT Therapeutics has recently been in the spotlight, especially in connection with podcasts and investor updates in March 2026. Here are the key points that have been discussed: Promising results in the ENACT study: In January and February, positive data was shared from the Phase II study (ENACT) on pancreatic cancer. The company reported that their technology is safe, and they saw a reduction in the biomarker CA 19-9 of over 85 % in patients, as well as significant tumor shrinkage. Extraordinary General Meeting (March 13, 2026): An extraordinary general meeting was recently held to issue new shares following the exercise of warrants, which strengthens the company's capital base for further studies. Future focus: CEO Per Walday has recently emphasized the potential of their "Acoustic Cluster Therapy" (ACT). He has spoken about how ultrasound can be used to target cancer treatment more effectively, and that they are also looking at opportunities within brain diseases. Important milestones: There is great anticipation for the next results (interim efficacy) from the ENACT study, which are expected around mid-2026. The company now presents itself as a "clinical-stage" company with a unique method to enhance the effect of chemotherapy using their proprietary solution, PS101, and ultrasound.
·27.1.Who is buying the share now? The conclusion triggers a potential redemption of up to 50.622.348 subscription rights in connection with the directed issue carried out on December 3rd. The exercise price per subscription right is 1,23 kroner, corresponding to a discount of 20 percent compared to the volume-weighted average price over the last three months.
·27.1.Can someone explain why there is potential redemption of 50.622.348 subscription rights here, when in the directed issue 3 Dec 2024 it states over 13 million subscription rights?·5.2.If you have that conversation with chatgpt, you will see that it is a "complicated" calculation that has many factors. One of them is, among other things, what was reported in the news today about "warrant exercise". So "fair value" (which cannot be used for much..) is 1,50 - 1,60 in short.- ·21.1.Here is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
Vain PDF
186 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11.3.Available on Spotify·16.3.Gemini seems to have taken a page from Spotify's book: EXACT Therapeutics has recently been in the spotlight, especially in connection with podcasts and investor updates in March 2026. Here are the key points that have been discussed: Promising results in the ENACT study: In January and February, positive data was shared from the Phase II study (ENACT) on pancreatic cancer. The company reported that their technology is safe, and they saw a reduction in the biomarker CA 19-9 of over 85 % in patients, as well as significant tumor shrinkage. Extraordinary General Meeting (March 13, 2026): An extraordinary general meeting was recently held to issue new shares following the exercise of warrants, which strengthens the company's capital base for further studies. Future focus: CEO Per Walday has recently emphasized the potential of their "Acoustic Cluster Therapy" (ACT). He has spoken about how ultrasound can be used to target cancer treatment more effectively, and that they are also looking at opportunities within brain diseases. Important milestones: There is great anticipation for the next results (interim efficacy) from the ENACT study, which are expected around mid-2026. The company now presents itself as a "clinical-stage" company with a unique method to enhance the effect of chemotherapy using their proprietary solution, PS101, and ultrasound.
- ·27.1.Who is buying the share now? The conclusion triggers a potential redemption of up to 50.622.348 subscription rights in connection with the directed issue carried out on December 3rd. The exercise price per subscription right is 1,23 kroner, corresponding to a discount of 20 percent compared to the volume-weighted average price over the last three months.·27.1.Can someone explain why there is potential redemption of 50.622.348 subscription rights here, when in the directed issue 3 Dec 2024 it states over 13 million subscription rights?·5.2.If you have that conversation with chatgpt, you will see that it is a "complicated" calculation that has many factors. One of them is, among other things, what was reported in the news today about "warrant exercise". So "fair value" (which cannot be used for much..) is 1,50 - 1,60 in short.
- ·21.1.Here is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 000 | - | - | ||
| 25 455 | - | - | ||
| 500 | - | - | ||
| 500 | - | - | ||
| 15 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 H2 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 25.9.2025 | ||
2024 H2 -tulosraportti 9.4.2025 | ||
2024 Q2 -tulosraportti 30.9.2024 | ||
2024 H1 -tulosraportti 30.9.2024 | ||
2023 Q4 -tulosraportti 18.4.2024 |
2025 H1 -tulosraportti
Vain PDF
186 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 H2 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 25.9.2025 | ||
2024 H2 -tulosraportti 9.4.2025 | ||
2024 Q2 -tulosraportti 30.9.2024 | ||
2024 H1 -tulosraportti 30.9.2024 | ||
2023 Q4 -tulosraportti 18.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11.3.Available on Spotify·16.3.Gemini seems to have taken a page from Spotify's book: EXACT Therapeutics has recently been in the spotlight, especially in connection with podcasts and investor updates in March 2026. Here are the key points that have been discussed: Promising results in the ENACT study: In January and February, positive data was shared from the Phase II study (ENACT) on pancreatic cancer. The company reported that their technology is safe, and they saw a reduction in the biomarker CA 19-9 of over 85 % in patients, as well as significant tumor shrinkage. Extraordinary General Meeting (March 13, 2026): An extraordinary general meeting was recently held to issue new shares following the exercise of warrants, which strengthens the company's capital base for further studies. Future focus: CEO Per Walday has recently emphasized the potential of their "Acoustic Cluster Therapy" (ACT). He has spoken about how ultrasound can be used to target cancer treatment more effectively, and that they are also looking at opportunities within brain diseases. Important milestones: There is great anticipation for the next results (interim efficacy) from the ENACT study, which are expected around mid-2026. The company now presents itself as a "clinical-stage" company with a unique method to enhance the effect of chemotherapy using their proprietary solution, PS101, and ultrasound.
- ·27.1.Who is buying the share now? The conclusion triggers a potential redemption of up to 50.622.348 subscription rights in connection with the directed issue carried out on December 3rd. The exercise price per subscription right is 1,23 kroner, corresponding to a discount of 20 percent compared to the volume-weighted average price over the last three months.·27.1.Can someone explain why there is potential redemption of 50.622.348 subscription rights here, when in the directed issue 3 Dec 2024 it states over 13 million subscription rights?·5.2.If you have that conversation with chatgpt, you will see that it is a "complicated" calculation that has many factors. One of them is, among other things, what was reported in the news today about "warrant exercise". So "fair value" (which cannot be used for much..) is 1,50 - 1,60 in short.
- ·21.1.Here is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 000 | - | - | ||
| 25 455 | - | - | ||
| 500 | - | - | ||
| 500 | - | - | ||
| 15 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt